当前位置： SCI文献检索 > BMC CANCER期刊下所有文献 > UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.

Abstract：

BACKGROUND:Uridine 5'-diphosphate-glucuronosyltransferase 2B (UGT2B) genes code for enzymes that catalyze the clearance of testosterone, dihydrotestosterone (DHT), and DHT metabolites in the prostate basal and luminal tissue. The expression of the UGT2B15, UGT2B17, and UGT2B28 enzymes has not been evaluated in prostate tissue samples from hormone therapy-naïve patients. METHODS:We determined the expression of UGT2B15, UGT2B17, and UGT2B28 enzymes in 190 prostate tissue samples from surgical specimens of a multiethnic cohort of patients undergoing radical prostatectomy at the Durham Veterans Affairs Medical Center. The association between each protein's percent positive and H-score, a weighted score of staining intensity, and the risk of biochemical recurrence (BCR) was tested using separate Cox proportional hazards models. In an exploratory analysis, UGT2B17 total positive and H-score were divided at the median and we tested the association between UGT2B17 group and risk of BCR. RESULTS:The median follow-up for all patients was 118 months (IQR: 85-144). Of 190, 83 (44%) patients developed BCR. We found no association between UGT2B15 or UGT2B28 and risk of BCR. However, there was a trend for an association between UGT2B17 and BCR (HR = 1.01, 95% CI 1.00-1.02, p = 0.11), though not statistically significant. Upon further investigation, we found that patients with UGT2B17 higher levels of expression had a significant increased risk of BCR on univariable analysis (HR = 1.57, 95% CI 1.02-2.43, p = 0.041), although this association was attenuated in the multivariable model (HR = 1.50, 95% CI 0.94-2.40, p = 0.088). CONCLUSIONS:Our findings suggest that UGT2B17 overexpression may be associated with a significant increased risk of BCR. These results are consistent with previous reports which showed UGT2B17 significantly expressed in advanced prostate cancer including prostate tumor metastases.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Grant DJ,Chen Z,Howard LE,Wiggins E,De Hoedt A,Vidal AC,Carney ST,Squires J,Magyar CE,Huang J,Freedland SJ

doi

10.1186/s12885-017-3463-6

subject

Has Abstract

pub_date

2017-07-03 00:00:00

pages

463

issue

issn

1471-2407

pii

10.1186/s12885-017-3463-6

journal_volume

pub_type

杂志文章

在线工具

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.